CFD
ESPR

Creative Financial Designs’s Esperion Therapeutics ESPR Stock Holding History

Creative Financial Designs’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-275
Closed -$1K – 1267
2022
Q1 		$1K Hold
275
– – ﹤0.01% 1202
2021
Q4 		$1K Hold
275
– – ﹤0.01% 1163
2021
Q3 		$3K Hold
275
– – ﹤0.01% 1243
2021
Q2 		$6K Buy
+275
New +$6.62K ﹤0.01% 1121

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Creative Financial Designs's ESPR Position: Q2 2022 in Review

Creative Financial Designs sold out of Esperion Therapeutics (ESPR) in Q2 2022, closing a stake of 275 shares — an estimated $1K sold.

Creative Financial Designs first reported a position in ESPR in Q2 2021 and held it in 4 quarters. The position peaked at $6K in Q2 2021. 136 funds tracked by Wall St. Rank hold ESPR as of Q2 2022.

  • Creative Financial Designs reported no remaining Esperion Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Creative Financial Designs sold 275 Esperion Therapeutics shares in Q2 2022, an estimated $1K.
  • Creative Financial Designs first reported a position in Esperion Therapeutics in Q2 2021 and held it in 4 quarters.
  • Creative Financial Designs's Esperion Therapeutics position peaked at $6K in Q2 2021.
  • 136 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2022.

Based on Creative Financial Designs's 13F filing for Q2 2022, filed 1 Aug 2022.